

Structure–Activity Relationships | Hot Paper |

Enhancing Potency and Selectivity of a DC-SIGN Glycomimetic Ligand by Fragment-Based Design: Structural Basis

Laura Medve^{+, [a]} Silvia Achilli^{+, [b]} Joan Guzman-Caldentey^{+, [c]} Michel Thépaut,^[b]
Luca Senaldi,^[a] Aline Le Roy,^[b] Sara Sattin,^[a] Christine Ebel,^[b] Corinne Vivès,^[b]
Sonsoles Martin-Santamaria,^{*, [c]} Anna Bernardi,^{*, [a]} and Franck Fieschi^{*, [b]}

Abstract: Chemical modification of pseudo-dimannoside ligands guided by fragment-based design allowed for the exploitation of an ammonium-binding region in the vicinity of the mannose-binding site of DC-SIGN, leading to the synthesis of a glycomimetic antagonist (compound **16**) of unprecedented affinity and selectivity against the related lectin langerin. Here, the computational design of pseudo-dimannoside derivatives as DC-SIGN ligands, their synthesis, their

evaluation as DC-SIGN selective antagonists, the biophysical characterization of the DC-SIGN/**16** complex, and the structural basis for the ligand activity are presented. On the way to the characterization of this ligand, an unusual bridging interaction within the crystals shed light on the plasticity and potential secondary binding sites within the DC-SIGN carbohydrate recognition domain.

Introduction

DC-SIGN is a transmembrane C-type lectin expressed at the surface of dendritic cells. It plays a key role in the recognition of several pathogens and in the development of various infections, including Dengue and the HIV virus.^[1] Over the past decade, several glycomimetic ligands have been designed to act as antagonists of DC-SIGN mediated viral infections by using as template the pseudo-dimannoside (ps-diMan) scaffold **1** (Figure 1A), composed of a mannose ring connected to a conformationally locked cyclohexane diol. Chemical modifications of both the cyclohexane appendages and the 6-position




Figure 1. A) The structure of known DC-SIGN antagonists with a pseudo-dimannoside core. B) X-ray structure of DC-SIGN/**1** complex PDB 2XR5: the 2-hydroxyl group of the mannose ring (Man-O2) points towards the Phe313 side-chain.

[a] Dr. L. Medve,⁺ L. Senaldi, Prof. S. Sattin, Prof. A. Bernardi
Dipartimento di Chimica, Università degli Studi di Milano
via Golgi 19, 20133, Milano (Italy)
E-mail: anna.bernardi@unimi.it

[b] Dr. S. Achilli,⁺ Dr. M. Thépaut, A. Le Roy, Dr. C. Ebel, Dr. C. Vivès,
Prof. F. Fieschi
Université Grenoble Alpes, CNRS, CEA
Institut de Biologie Structurale, 38044 Grenoble (France)
E-mail: franck.fieschi@ibs.fr

[c] J. Guzman-Caldentey,⁺ Dr. S. Martin-Santamaria
Department of Structural and Chemical Biology
Centro de Investigaciones Biológicas, CIB-CSIC
C/Ramiro de Maeztu, 9, 28040 Madrid (Spain)
E-mail: smsantamaria@cib.csic.es

[⁺] These authors contributed equally to this work.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/chem.201903391>.

© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of Creative Commons Attribution NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

of mannose, as in **2** and **3**, led to improvements in the affinity of the ligands towards DC-SIGN—which remains modest (from a 0.9 mM IC₅₀ of **1** in SPR inhibition experiments to 0.3–0.2 mM for **2** and **3**) but can be magnified by their polyvalent presentation.^[2] Most importantly, these structural modifications also led to improved selectivity against the related C-type lectin langerin, which could be explained by comparative structural analysis of the two proteins.^[3]

In this work, we describe our efforts to improve the affinity of the pseudo-dimannoside ligands by computational design, using a fragment-based screening in the X-ray structure of DC-SIGN carbohydrate recognition domain (CRD) in complex with **1** (PDB 2XR5; PDB=Protein Data Bank). This screening identified several moieties, predicted to bind to sites adjacent to the bound pseudo-dimannoside, and potentially amenable to modify its structures. Among them, we focused on fragments that favorably interact in the proximity of Phe313. This region, which is involved in binding several natural oligomannosides,^[4] is near the 2-hydroxyl group of the mannose ring (Man-O2) in

the DC-SIGN/ **1** complex (Figure 1B). Pseudo-dimannoside structures could be therefore expanded at this position and could, in principle, engage more productively with the protein, while remaining easily chemically accessible. The newly designed compounds derived from **1** were predicted to bind in the DC-SIGN CRD with favorable interactions. As opposed to screening of non-glycan small molecules, the present approach takes advantage of a natural sugar element to direct the ligand to the CRD, thus avoiding off-target effects and interaction with other hot spots of the protein, which have been suggested to allosterically influence glycan binding.^[5]

Results and Discussion

Fragment-based virtual screening and ligand design

To locate vicinal pockets as putative additional binding regions, we explored the surrounding of the pseudo-dimannoside binding site of DC-SIGN. A virtual screening (VS) of the Maybridge database (over one thousand drug-like fragments, www.maybridge.com) was performed by means of Glide using as starting point the crystallographic structure of DC-SIGN in complex with **1** (PDB 2XR5). The center of the VS box was placed at the centroid among residues Phe313, Ser360 and Lys373, and was expanded by 10 Å in each *x*, *y* and *z* axis. A total of 50 fragments were selected (5% best docked fragments) for visual inspection. Most of the fragments were placed in the region enclosed by residues Asn344, Glu358, Ser360, Asn365, Asp367, Phe313, Leu371 and Lys373 (Figure 2A) and they all bore an ammonium moiety and an aromatic ring. The ammonium group was docked into an “ammonium-binding pocket” in close proximity to the Ca²⁺ binding site and lined by Phe313, Glu358 and Ser360. Stabilizing interactions thus include ion pair with Glu358 side chain, hydrogen bond with Ser360 side chain, and cation- π contacts with Phe313 phenyl ring (Figure 2A). Interestingly, the ammonium-binding pocket identified by virtual screening corresponds to a region occupied by highly conserved water molecules in the known X-ray structures of DC-SIGN and its sugar complexes (PDB 2IT5, 2IT6, 2XR5, 1SL4 and 1K9I). The aromatic moiety of the fragments (either a phenyl or a heterocyclic ring) was found docked close to Phe313, Asn344 and Leu371 side chains and established π - π or CH- π interactions with these residues. Other fragments were predicted to bind outside the ammonium-binding pocket, but were not prioritized for further design and synthesis.





Figure 2. A) Selected superimposed fragments from virtual screening into the DC-SIGN/**1** complex (PDB 2XR5). The red box highlights the ammonium-binding site and the main residues that flank it. B) Selected newly designed compounds with general structure **5**. Superimposed docked poses into the average structure of DC-SIGN from MD simulations are shown.

Excitingly, the pose of the fragments docked into the ammonium-binding pocket clearly allowed for conjugation to the position 2 of the mannose ring of ps-diMan **1**, a position with many opportunities for functionalization not completely exploited so far. Among the possibilities explored, we focused on structures that can be easily accessible starting from the 2-azido derivative of **1** (compound **4** in Scheme 1) and using Copper(I)-catalyzed Alkyne Azide Cycloaddition (CuAAC) reaction with α -aminoalkynes, to afford the amino triazoles **5** (Scheme 1). Thus, a number of derivatives of general formula **5** were computationally built as putative ligands (including the *S* and *R* configurations; Figures 3 and Figure S1 in the Supporting Information) and docked in the DC-SIGN CRD (Figure 2B),



Scheme 1. Putative ligands designed for docking analysis and synthesis.





Figure 3. Triazole derivatives synthesized and tested as DC-SIGN ligands.

to predict their binding capability. The details of the calculations are reported in the Supporting Information.

The designed compounds were docked in three different DC-SIGN conformations: two from the X-ray crystallographic structures 2XR5 and 2IT5 (differing in some side chains orientations of the residues close to the carbohydrate binding site, Figure S2 in the Supporting Information), and a third one obtained as an average from the molecular dynamics (MD) simulation of apo DC-SIGN from PDB 2XR5, in which rotamers of Val351 were observed. All designed compounds were predicted to bind the CRD mannoside-binding site with the pseudo-dimannoside moiety bound in similar pose to that of **1** in the complex with DC-SIGN (PDB 2XR5). The triazole moiety has optimal orientation to reach the ammonium-binding pocket and to allow the ammonium group to interact with Phe313 and Glu358 side chains (Figure 2B and Figure S3 in the Supporting Information). On this basis, the synthesis of several triazole derivatives **5** was planned and executed as described below and selected DC-SIGN/5 complexes were also submitted to MD simulations (see below).

Synthesis

For the synthesis of the 2-azido pseudo-dimannoside **4**, glycosyl donor **9** was prepared in three steps starting from D-mannosamine hydrochloride **6** (Scheme 2). Compound **6** was converted into the corresponding azide **8** by diazotransfer with imidazole-1-sulfonyl azide hydrogensulfate **7**,^[6] as previously described for GlcNH₂ and GalNH₂. Applying the same reaction conditions to ManNH₂ **6** initially led to poor yields and irreproducible results. Alternative procedures for the preparation of 2-deoxy-2-azidoMan derivatives have indeed been reported in the literature as producing *manno-gluco-* mixtures, in which the *gluco-* like impurities are often ascribed to contamination of the mannosamine starting material.^[7] We found that formation of the *gluco-* by-product (GlcN3) during the diazotransfer is actually due to epimerization at position 2, promoted by the



Scheme 2. Synthesis of the ligands. i) **7**, K₂CO₃, CuSO₄·5H₂O, MeOH, −20 °C to R.T., 4 h; ii) Ac₂O, Py, RT, 12 h, 90% over two steps; iii) MeNH₂, THF, 0 °C–R.T., 5 h, 97%; iv) Cl₃CCN, DBU, CH₂Cl₂, 0 °C, 30 min, 79%; v) **9**, TMSOTf, CH₂Cl₂, −30 °C, 1 h, 95%; vi) CuSO₄·5H₂O, Na ascorbate, THF/water; vii) MeO-Na, MeOH, RT, 30 min.

excess of potassium carbonate. Stepwise addition of K₂CO₃ at low temperature (−20 °C) and careful pH control allow to avoid epimerization and to obtain reproducible high yields (90%) of pure 1,3,4,6-tetra-*O*-acetyl-2-deoxy-2-azidoMan **8**, from which the 2-deoxy-2-azidomannosyl donor **9** was obtained following established protocols.^[8]

The known acceptor **10**^[3a] was glycosylated with **9** in the presence of a catalytic amount of TMSOTf, affording the desired common intermediate **11** in 90% overall yield. Reaction of the azide **11** with alkynes through CuAAC^[9] followed by Zemplén deprotection afforded the triazole derivatives **5** and **12–16** (Scheme 2 and Figure 3), as detailed in the Supporting Information. The required alkynes were either commercially available, or prepared in a few steps, as described in the Supporting Information (Figure S7, Supporting Information). The synthesis of aryl-propargyl amines in enantiomerically pure form is not trivial.^[10] For this preliminary screening we prepared triazole **5d** (Figure 3) as an epimeric mixture at the N-bearing stereocenter by using the corresponding racemic propargyl amine (commercially available). The two isomers proved to be chromatographically inseparable, just as the corresponding methyl derivatives **5c**, and both molecules were tested as diastereomeric mixtures. On the contrary, the benzyl alcohols **15b** (Figure 3) synthesized as an epimeric mixture from (±)-1-phenylpropynol could be separated chromatographically and were tested as individual isomers, although the configuration of the benzylic stereocenter was not assigned (**15bR/S** and **15bS/R** in Figure 3). The 2- and 3-pyridyl derivatives **13** and **14** were synthesized from the corresponding commercially available alkynes.

SPR competition assay

The compounds obtained were tested by surface plasmon resonance (SPR) as potential inhibitors of DC-SIGN interaction with an immobilized mannosylated bovine serum albumin (BSA). The IC₅₀ values obtained from the SPR inhibition assays for the triazole derivatives and their parent compounds **1–3** (Figure 1A) are plotted in Figure 4A and the corresponding values collected in Table S1 (Supporting Information). In bearing with the computational predictions for the ammonium-binding site, the methylenamino triazole derivative **5a** gave an IC₅₀ of 108 ± 1 μM, with one order of magnitude improvement over the parent ps-diMan **1**. Addition of methyl substituents on the α carbon of the triazole ring, as in **5b,c** was detrimental for the affinity. Similarly, additional methyl groups on the nitrogen atom, meant to stabilize the positive charge as in **12a–c**, led to a significant decrease in affinity. Collectively, these data suggest a negative effect of steric hindrance at, or near to, the ammonium-binding site. Interestingly, ligand **15a**, in which the amine is replaced by a hydroxyl group, also provided a three-fold affinity improvement over **1** (IC₅₀ of 339 ± 7 μM) suggesting a positive role of H-bonding ability in that position. Indeed, docking of **15a** yielded a pose that placed the OH group into the ammonium-binding site (not shown). This result is also in agreement with the observation that the ammonium-binding site identified by VS overlaps with a highly




Figure 4. A) IC₅₀ of triazoles derivatives towards DC-SIGN (corresponding numerical values in Table S1); B) SPR inhibition assay for **5a** (green), **13** (red) and **16** (blue). Inhibition curves of DC-SIGN (circle) and langerin (square) binding to a mannosylated surface are shown.

conserved hydration site in the DC-SIGN CRD crystals. The effect of aromatic substituents on the α carbon of the triazole ring was more difficult to dissect, because the epimeric mixture of α -phenyl derivatives **5d** could not be separated. SPR analysis of the mixture yielded an IC₅₀ of $407 \pm 7 \mu\text{M}$ (Figure 4A), indicating a fourfold loss of activity relative to **5a**. Luckily, the corresponding epimeric alcohols **15bR/S** and **15bS/R** could be separated by flash chromatography and were tested separately in the inhibition experiment, yielding an IC₅₀ value of $870 \pm 1 \mu\text{M}$ and $590 \pm 4 \mu\text{M}$, respectively. Thus, none of the epimers provided an improvement over the parent alcohol **15a**. Alternatively, the 2-pyridyltriazole **13**, which does not feature a positive charge at the pH of the assay (pH 8), but presents the pyridine nitrogen adjacent to the triazole ring, afforded an IC₅₀ $180 \pm 6 \mu\text{M}$ and, thus, a very significant improvement over **1**. This suggests that the pyridine moiety can be engaged in stabilizing (lipophilic) contacts with the protein surface. Docking calculations predict the pyridine ring to be involved in edge-to-face interactions with the Phe313 side chain and possibly in H-bonding interaction with Lys373. Indeed, the position of the pyridine nitrogen appears to play a crucial role, since the 3-pyridyl derivative **14**, with an IC₅₀ $609 \pm 6 \mu\text{M}$, shows a fivefold loss of activity relative to **13**. Overall, functionalization of the mannose residue with a triazole ring carrying an ammonium group was found to increase the DC-SIGN affinity, as expected based on the computational models. So far, the beneficial effects of an aromatic substituent have not been fully confirmed by the limited set of compounds synthesized and analyzed.

Based on the SPR results, **5a** was chosen as lead compound for transformation into **16** (Figure 3), which combines the backbone structure of **2** (carrying two *p*-hydroxymethylene-benzamide substituents on the cyclohexane ring) and the functionalization of **5a** at mannose C-2. As mentioned above, **2** has an enhanced affinity towards DC-SIGN compared to **1** (IC₅₀ = $329 \mu\text{M}$ and $956 \mu\text{M}$ for **2** and **1**, respectively) and is significantly more selective against langerin.^[3a] Thus, this switch of scaffold was expected to improve both affinity and selecti-

ty of the ammonium-carrying ligand. SPR binding inhibition studies were performed for **16** and DC-SIGN affording an IC₅₀ of $76 \pm 3 \mu\text{M}$ (Figure 4A). Additionally, **5a**, **13** and **16** were also tested against langerin: selectivity towards DC-SIGN increased from **5a** to **13** and reached a maximum with **16** (Figure 4B). Thus, **16** is the most effective and selective mannose-based glycomimetic antagonist developed to date against DC-SIGN.

Biophysical characterization of **16** binding to DC-SIGN

To further characterize the binding interaction of **16** with DC-SIGN, an ITC titration was performed. Ligand **16** (2.5 mM) was titrated into a DC-SIGN solution (100 μM) (Figure S5A, Supporting Information). A one binding site model fitting of the data with an assumed stoichiometry value fixed to 1 yielded an equilibrium dissociation constant K_D of $52.0 \pm 1.3 \mu\text{M}$, in agreement with the IC₅₀ determined by competition assay (IC₅₀ $76 \pm 3 \mu\text{M}$). The high affinity of **16** for DC-SIGN also allowed for the evaluation of the interaction in a SPR direct binding mode by using a DC-SIGN functionalized surface.^[11] The resulting K_{Dapp} from steady state fitting was found to be $52.7 \pm 2.7 \mu\text{M}$ (Figure S5B, Supporting Information) in good agreement with the results obtained by ITC. The ITC analysis yielded $\Delta H = -19.6 \pm 0.2 \text{ kJ mol}^{-1}$ and a $T\Delta S = 4.9 \pm 0.2 \text{ kJ mol}^{-1}$, leading to a ΔG of $-24.46 \text{ kJ mol}^{-1}$. Thus, **16** binding is mainly enthalpically driven, potentially due to the additional interactions brought by the amino group added in **16**.

X-ray crystallography

Co-crystallization experiments of DC-SIGN CRD and **16** were conducted. Crystals were obtained and their structure was solved at 2.1 Å resolution (PDB 6GHV). The data revealed a totally new crystal packing, compared to previous DC-SIGN structures, with an asymmetric unit composed of six CRDs and six molecules of **16** (Figure 5A). This crystal packing (space group $P12_11$) is enabled by each ligand molecule reaching out to a second CRD unit, thus forming a symmetric network (Fig-




Figure 5. Crystallization packing dependence on **16**. A) Crystal packing within crystals of the DC-SIGN CRD/**16** complex, dark square is zoomed in B). B) Omit map of **16** highlighting its position at the interface of three CRD units. The majority of interactions occur with two of the CRDs (cyan and orange chains). C) Symmetrical dimer of CRDs bridged by two molecules of **16**. Both ligands are bound to one of the CRDs through the canonical Ca^{2+} ion site and establish an additional interaction with a second CRD, involving one benzylamide arm of **16** and a cavity between helix 2 and the loop upstream of the CRD $\beta 5$ strand. Pink spheres are Ca^{2+} ions, green spheres are chloride ions.

ure 5C). Each ligand therefore bridges the canonical Ca^{2+} binding site in one CRD and a cavity generated between helix 2 and the following loop upstream of the $\beta 4$ strand of the next CRD (Figure 5C). As expected, the Ca^{2+} ion is coordinated by Man-O3 and Man-O4, while the noncanonical site in the next CRD is occupied by one of the *p*-hydroxymethylenebenzylamide substituents of **16**. In addition to these two main interactions sites, **16** is also in contact with a neighboring third CRD (the green chain in Figure 5B), thanks to the second benzylamide arm. The binding mode of **16**, due to the extended interaction with DC-SIGN CRDs in this packing, is very well defined, allowing a fine analysis within each different binding site (Figure 5B,C as well as Figures 6 and 7). Compared to the X-ray structure of DC-SIGN/**1** complex, the two additional fragments of **16** that make contact with the protein, both the ammonium group and the intercalated benzylamide arm, point to druggable secondary sites recently identified by Aretz et al.^[12] (Figure S6, Supporting Information).

The noncanonical interaction site that determines the bridge between CRDs by **16** in the crystals is shown in Figure 6. The overlay of the backbone structures of DC-SIGN CRD (PDB 1K9I, Figure 6, pink) with the structure of our complex (Figure 6, cyano) shows a conservation of structural elements, with the exception of a kink in helix 2. This helix movement results from the insertion of a *p*-hydroxymethylenebenzylamide arm between the helix and a facing loop (Figure 6). Backbone CO group from Ser271 provides stabilizing H-bond with the benzylic hydroxy group of **16** through a bridging water molecule




Figure 6. Non-canonical binding site of **16**. A) Overlay of DC-SIGN CRD X-ray structure (pink, PDB 1K9I) and DC-SIGN CRD co-crystallized with **16** (cyan, PDB 6GHV) highlighting the kink of helix-2 due to insertion of the *p*-hydroxymethylenebenzylamide fragment. A second copy of **16** in its canonical Ca^{2+} binding site can be seen in the back of the Figure, where the Ca^{2+} ion is shown in magenta. B) and C) The comparison between the two CRDs shows the cavity generated by Arg312 movement (see in A).

(Figure 6A), whereas a large movement of Arg312 generates the required cavity (compare Figure 6B and C) and provides additional stabilization through H-bond with the amide carbonyl (Figure 6A). These structural adjustments for the *p*-hydroxymethylenebenzylamide arm illustrate the plasticity of the CRD backbone of DC-SIGN as previously observed for langerin.^[13]

In the crystal, **16** interacts similarly to the previously characterized binding mode for the glycomimetics **1–3**^[3,14] exploiting Val351 side chain for nonpolar interactions with the cyclohexane ring. Here, for the first time, details of the interaction of the benzylamide arm with the primary CRD surface, previously suggested by NMR studies, are highlighted. Thus, the amide carbonyl is H-bonded to Lys368 in the CRD, the benzyl ring is in van der Waals contact with the loop containing Val351 and Gly352 and the terminal OH group is involved in a H-bonding network with the protein surface through two water molecules (Figure 7A). These results are in agreement with MD calculations of the complex, which anticipated one of the benzylamide arms to be dangling in the solvent (thus becoming available for the secondary interactions described above) and the second one oscillating CH- π interactions with Val351 and Gly352, whereas its terminal hydroxyl group alternates H-bonds with the backbone CO of Asn350, Gly352 NH and solvent water molecules (Figure 7C and Figure S4 in the Supporting Information). The additional ammonium group, connected to mannose C-2 through a triazole linker, reaches Ser360 and Glu358, as initially predicted from the docking analysis. Inter-




Figure 7. A) Binding mode of **16** in the canonical Ca^{2+} binding site of DC-SIGN (PDB 6GHV). H bonds are represented in yellow, van der Waals and cation- π interactions with Phe313 in green. Ca^{2+} ions are represented as magenta sphere. B) The same complex. View rotated by 180° and protein represented as electrostatic surface. C) 3D Structure of DC-SIGN (cyan) in complex with compound **16** (blue) from MD simulation. Superimposed crystallographic (yellow, PDB 6GHV) and docked (magenta) poses of compound **16** are depicted.

estingly, also the MD simulations of DC-SIGN/**16** described a stable complex, with the ammonium group interacting with Phe313 and Glu358 side chains during the entire simulation time (100 ns, Figure S4, Supporting Information). In this posi-

tion, a cation- π interaction is also generated with Phe313, as expected from the distance of 3.3 Å between the ammonium group and the phenyl ring (Figure 7A). The cumulative interactions resulting from the ammonium ion may account for the improved enthalpy contribution to the binding observed in the ITC studies described above. In Figure 7B, the CRD representation as electrostatic surface potential highlights the negative potential favoring ammonium binding.

Due to the peculiar position of **16** at the interface of three CRDs in the crystal packing, the relevance of the binding mode observed in the Ca^{2+} binding site could be questioned. However, the conservation of the binding mode observed with **1** and **2**, from which **16** is derived, and the perfect correlation of the ammonium group binding pocket with the computational prediction support the coherence of the complex structure observed. The question remains whether the unexpected bridging interaction observed in the crystal may also be present in solution and account for the improved affinity of **16** for DC-SIGN. Bridging of DC-SIGN tetramers by glycomimetic ligands in solution has been previously observed and characterized by analytical ultracentrifugation (AUC) with a pseudo-trimannoside compound.^[15] Thus, to discriminate between a crystallization-induced artefact and a genuine additional binding site in solution, AUC experiments were performed by using either DC-SIGN CRD (Figure 8A, crystallization condition) or the full tetrameric extracellular domain (ECD, Figure 8B) at fixed concentration (56 and 26 μM , respectively), while increasing




Figure 8. AUC analysis of A) DC-SIGN CRD/**16** complex and B) DC-SIGN ECD/**16** complex in solution.

the concentration of **16**. For the CRD, the sedimentation coefficient remained unchanged to a value around 1.8 S ($s_{20,w} = 2.1$ S), at all the used concentrations of **16**, showing the absence of dimerization and, therefore, the absence of a clustering effect of **16** towards DC-SIGN CRD in solution, as opposed to the crystal context. The same was found for DC-SIGN ECD, which sedimented as a tetramer at 4.5 S ($s_{20,w} = 5.4$ S, close to the previously published), alone and in the presence of **16**.^[15,16] From this last characterization, we can assume that only binding in the canonical Ca^{2+} site exists in solution and is by itself responsible for the unprecedented affinity observed with this glycomimetic.

Conclusion

In summary, chemical modification of the known glycomimetic ligand **1** guided by fragment-based design allowed for the exploitation of an ammonium-binding region in the vicinity of the sugar-binding site of DC-SIGN, improving by one order of magnitude the inhibitory potency. ITC confirmed that the novel antagonist **16**, with a K_D of $52 \pm 1 \mu\text{M}$, is among the most potent monovalent DC-SIGN ligands so far described,^[17] whereas SPR analysis showed that it is also fully selective for DC-SIGN versus langerin. The X-ray structure of the DC-SIGN/**16** complex fully validated the modeling prediction and offered a structural basis for the result interpretation. In particular, the presence of an ammonium ion in **16** contributes simultaneously to the high affinity for DC-SIGN, by interacting with an ammonium-binding region in the vicinity of Phe313, and to the selectivity for DC-SIGN vs. langerin, which harbors a largely positive binding site rich in lysine residues.^[3b] AUC analysis convincingly confirmed that the affinity increase observed for **16** relative to previous pseudo-dimannoside-type ligands is not due to induced aggregation of soluble DC-SIGN CRD. Altogether, these features make **16**, originated from a fragment-based design approach, the best glycomimetic developed to date to efficiently target DC-SIGN. In addition, the intriguing features observed in the X-ray structure of the DC-SIGN/**16** complex offer a glimpse of the plasticity of the receptor CRD, which is likely to be central to a full understanding of its machinery.

Experimental Section

Computational methods

Virtual screening was performed by using Glide and the Maybridge Ro3 core set fragment library. Ligand docking was performed by using AutoDock 4 and the MD simulations using AMBER14. The experimental details are reported in the Supporting Information.

Syntheses

General experimental conditions are reported in the Supporting information. 3-Azidosulfonyl-3H-imidazol-1-ium hydrogen sulfate **7** was synthesized as described in Ref. [6b]. The alkynes used for the CuAAC reactions are collected in Figure S7 (Supporting Information). The synthesis of the non-commercially available alkynes and

the full synthesis of **16** are described in the Supporting information.

1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-mannopyranose (8): D-Mannosamine hydrochloride (1.2050 g, 5.59 mmol, 1 molequiv) was suspended in dry MeOH (50 mL) and cooled to -20°C . K_2CO_3 (811 mg, 5.87 mmol, 1.05 mol equiv) was dissolved in 4 mL water and added to the stirred suspension. $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (14 mg, 0.06 mmol, 0.01 molequiv) was added to the mixture. Another portion of K_2CO_3 (811 mg, 5.87 mmol, 1.05 molequiv) in 4 mL water was added, immediately followed by the addition of imidazole-1-sulfonyl azide (1.8190 g, 6.7080 mmol, 1.2 molequiv). The pH was continuously controlled and the reaction was stirred at -20°C for 2 hours, when it was left to warm to RT (light-blue suspension). After 4 hours, only one major spot was detected by TLC ($R_f = 0.4$ in 8:2 $\text{CH}_2\text{Cl}_2/\text{MeOH}$). The solvent was evaporated in vacuo and the crude was suspended in dry pyridine (20 mL). The mixture was cooled to 0°C and Ac_2O (4.22 mL, 44.72 mmol, 8 molequiv) was added dropwise. The reaction was stirred overnight at RT and the next day only one major spot was detected on TLC ($R_f = 0.36$ in toluene/EtOAc = 9:1). The crude was purified by flash chromatography (toluene/EtOAc = 9:1) to yield the pure product **8** as a white foam (1.9 g, 92%), $\alpha/\beta = 2:1$. α -anomer: $^1\text{H NMR}$ (400 MHz, CDCl_3): $\delta = 6.09$ (d, 1H, H_1 , $J_{1,2} = 1.9$ Hz), 5.43–5.34 (m, 2H, H_3 , H_4), 4.21 (dd, 1H, H_{6a} , $J = 4.6$ Hz, $J = 12.4$ Hz), 4.08 (dd, 1H, H_{6b} , $J = 2.2$ Hz, $J = 12.4$ Hz), 4.04–3.98 (m, 2H, H_2 , H_5), 2.16 (s, 3H, AcO), 2.11 (s, 3H, AcO), 2.09 (s, 3H, AcO), 2.05 ppm (s, 3H, AcO); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): $\delta = 170.6$ (C=O (AcO)); 169.9 (C=O (AcO)); 169.3 (C=O (AcO)); 168.1 (C=O (AcO)); 91.7 (C_1); 71.1 (C_3); 71.1 (C_5); 65.6 (C_4); 62.1 (C_6); 60.1 (H_2); 21.2 (Me (OAc)); 20.9 (Me (OAc)); 20.9 (Me (OAc)); 20.8 ppm (Me (OAc)).

β -anomer: $\delta = 5.81$ (d, 1H, H_1 , $J_{1,2} = 1.4$ Hz), 5.27 (t, 1H, H_4), 5.04 (dd, 1H, H_3 , $J = 3.7$ Hz, $J = 9.8$ Hz), 4.23 (dd, 1H, H_{6a} , $J = 4.9$ Hz, $J = 12.4$ Hz), 4.06 (dd, 1H, H_{6b} , $J = 2.4$ Hz, $J = 12.4$ Hz), 4.04–3.98 (m, 1H, H_2), 3.70 (ddd, 1H, H_5 , $J = 2.4$ Hz, $J = 4.9$ Hz, $J = 9.9$ Hz), 2.18 (s, 3H, AcO), 2.11 (s, 3H, AcO), 2.08 (s, 3H, AcO), 2.04 ppm (s, 3H, AcO). $^{13}\text{C NMR}$ (100 MHz, CDCl_3): $\delta = 170.6$ (C=O (AcO)); 169.9 (C=O (AcO)); 169.3 (C=O (AcO)); 168.1 (C=O (AcO)); 91.5 (C_1); 73.6 (C_5); 72.2 (C_3); 65.3 (C_4); 62.1 (C_6); 61.4 (H_2); 21.1 (Me (OAc)); 21.1 (Me (OAc)); 21.0 (Me (OAc)); 20.9 ppm (Me (OAc)).

3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-mannopyranose (8): 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-mannopyranose **8** (506 mg, 1.36 mmol, 1 mol equiv) was dissolved in 1 mL dry THF and cooled to 0°C . 813 μL 2 M MeNH_2 in THF (1.63 mmol, 1.2 mol equiv) was added to the solution and the reaction was stirred at RT for 1.5 hours. After completion, the mixture was concentrated and the crude was purified by flash chromatography (R_f : 0.27 (α) and 0.24 (β) in toluene/EtOAc = 6:4). The product was obtained in 97% yield (437 mg) as a 87:13 α : β anomeric mixture. $^1\text{H NMR}$ (400 MHz, CDCl_3): α -anomer: $\delta = 5.45$ (dd, 1H, H_3 , $J_{2,3} = 3.8$ Hz, $J_{3,4} = 9.8$ Hz), 5.35 (t, 1H, H_4 , $J_{4,5} = 9.5$ Hz), 5.27 (s, 1H, H_1), 4.26–4.09 (m, 3H, $\text{H}_{6a,b}$, H_2), 4.06 (dd, 1H, H_2 , $J_{1,2} = 1.8$ Hz), 2.10 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.05 (s, 3H, OAc). β -anomer: $\delta = 5.29$ –5.23 (m, 1H, H_4), 5.13 (dd, 1H, H_3 , $J_{2,3} = 3.8$ Hz, $J_{2,3} = 9.9$ Hz), 4.91 (d, 1H, H_1 , $J_{1,2} = 6.4$ Hz), 4.26–4.10 (m, 2H, $\text{H}_{6a,b}$), 3.67–3.60 (m, 2H, H_5 , H_2), 2.12 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.05 ppm (s, 3H, OAc); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): α -anomer: $\delta = 170.8$ (C=O (AcO)); 170.0 (C=O (AcO)); 169.6 (C=O (AcO)); 92.8 (C_1); 70.7 (C_3); 68.6 (C_5); 65.9 (C_4); 62.2 (C_6); 61.7 (C_2); 20.8 (Me (OAc)); 20.7 (Me (OAc)); 20.6 (Me (OAc)). β -anomer: $\delta = 170.8$ (C=O (AcO)); 170.0 (C=O (AcO)); 169.6 (C=O (AcO)); 92.7 (C_1); 72.8 (C_3); 72.4 (C_5); 65.4 (C_4); 63.5 (C_2); 62.1 (C_6); 20.8 (Me (OAc)); 20.7 (Me (OAc)); 20.6 ppm (Me (OAc)); MS (ESI): m/z calculated for $[\text{C}_{12}\text{H}_{17}\text{N}_3\text{O}_8\text{Na}]^+$: 354.1 $[M+\text{Na}]^+$; found: 354.1.

2-Azido-2-deoxy-3,4,6-tri-O-acetyl-D-mannose trichloroacetimidate (9): 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-mannopyranose (400 mg, 1.20 mmol, 1 mol equiv) was dissolved in 5 mL CH₂Cl₂, cooled to 0 °C and trichloroacetonitrile (1.33 mL, 13.29 mmol, 11 mol equiv) was added to the solution. Then, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 45 μL, 0.30 mmol, 0.25 molequiv) was added and the reaction was stirred at RT under N₂ overnight. After completion, the mixture was concentrated and the crude was purified by flash chromatography (*R*_f: 0.38 in hexane/EtOAc = 75:25) to yield the pure product as a white foam (439 mg, 77% yield, exclusively α-product). [α]_D²⁰: +88.9° (*c* = 0.6 in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃): δ = 8.77 (s, 1H, NH), 6.29 (d, 1H, H₁, *J*₁₋₂ = 1.8 Hz), 5.45 (t, 1H, H₄, *J*₄₋₃ = *J*₄₋₅ = 10.0 Hz), 5.43 (m, 1H, H₃), 4.28 (dd, 1H, H₂, *J*₂₋₃ = 3.3 Hz), 4.25 (dd, 1H, H_{6a}, *J*_{6a-6b} = 12.7 Hz, *J*_{6a-5} = 4.8 Hz), 4.18–4.12 (m, 2H, H₅, H_{6b}), 2.12 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.07 ppm (s, 3H, OAc); ¹³C NMR (100 MHz, CDCl₃): δ = 170.8 (C=O (AcO)); 170.1 (C=O (AcO)); 169.6 (C=O (AcO)); 160.0 (C=NH); 95.5 (C₁); 90.42 (CCl₃); 71.4 (C₅); 70.8 (C₃); 65.2 (C₄); 61.8 (C₆); 60.0 (C₂); 20.9 (OAc); 20.8 (OAc); 20.7 ppm (OAc); MS (ESI): *m/z* calculated for [C₁₄H₁₇Cl₃N₄O₈Na]⁺: 497.01 [*M*+Na]⁺; found: 496.88.

1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-((3,4,6-O-triacetyl)-2-azido-α-D-2-deoxymannopyranosyloxy)-1,2-dimethylester (15,2S,4S,5S) (11): A mixture of the acceptor **10**^[3a] (124 mg, 0.42 mmol, 1 mol equiv) and the donor **9** (200 mg, 0.42 mmol, 1 molequiv) was co-evaporated with toluene three times. Powdered and activated 4 Å molecular sieves (acid washed) were added. The mixture was kept under vacuum for 3–4 hours and then dissolved in dry CH₂Cl₂ (10 mL). After cooling to –30 °C, trimethylsilyl trifluoromethanesulfonate (TMSOTf; 15.2 μL, 0.084 mmol, 0.2 mol equiv) was added to the stirred mixture. The solution was stirred at –30 °C for 1 hour and upon completion, the reaction was quenched with triethylamine (TEA). The mixture was warmed to room temperature and filtered over a Celite pad. The filtrate was evaporated at reduced pressure and the crude product was purified by flash chromatography (hexane/EtOAc = 72:28) to yield the pure product as a white foam (240 mg, 94% yield, exclusively α-product). [α]_D²⁰: +73.4° (*c* = 0.68 in CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 5.35 (dd, 1H, H₃, *J*₃₋₂ = 3.6 Hz, *J*₃₋₄ = 9.6 Hz), 5.29 (dd, 1H, H₄, *J*₄₋₅ = 9.4 Hz), 4.98 (d, 1H, H₁, *J*₁₋₂ = 1.5 Hz), 4.21 (dd, 1H, H_{6a}, *J*₆₋₅ = 5.4 Hz, *J*_{6-6b} = 12.2 Hz), 4.08 (dd, 1H, H_{6b}, *J*_{6b-5} = 2.3 Hz), 4.03 (m, 1H, H₂), 3.98–3.94 (m, 1H, H₅), 3.94–3.90 (m, 1H, C₂), 3.87–3.80 (m, 1H, H_{7a}), 3.70 (s, 3H, H₁₀), 3.69 (s, 3H, H₁₀), 3.68–3.64 (m, 1H, H_{7b}), 3.62–3.59 (m, 2H, H_{8a,b}), 3.59–3.58 (m, 1H, C₁), 3.02 (dt, 1H, C₄, *J*_{C4-C3eq} = 4.0 Hz, *J*_{C4-C3ax} = *J*_{C4-C5} = 12.0 Hz), 2.88 (dt, 1H, H_{C5r}, *J*_{C5-C6eq} = 4.0 Hz, *J*_{C5-C6ax} = 12.0 Hz), 2.10 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.10–1.80 ppm (m, 4H, H_{C3axr}, H_{C3eqr}, H_{C6eqr}, H_{C6axr}); ¹³C NMR (100 MHz, CDCl₃): δ = 174.9 (C₉); 174.6 (C₉); 170.8 (C=O (AcO)); 170.0 (C=O (AcO)); 169.6 (C=O (AcO)); 95.9 (C₁); 75.3 (C_{C1}); 71.7 (C_{C2}); 71.0 (C₃); 69.6 (C₇); 69.2 (C₅); 66.3 (C₄); 62.6 (C₆); 61.9 (C₂); 52.2 (C₁₀); 43.2 (C₈); 39.2 (C_{C5}); 39.0 (C_{C4}); 28.0, 26.8 (C_{C3r}, C_{C6}); 20.9 (Me (AcO)); 20.8 (Me (AcO)); 20.7 ppm (Me (AcO)); MS (ESI): *m/z* calculated for [C₂₄H₃₄ClN₃O₁₃Na]⁺: 630.17 [*M*+Na]⁺, found: 630.51

General procedure for CuAAC reactions. 1 M CuSO₄·5H₂O and Na ascorbate solutions were prepared in degassed water. The alkyne (1 molequiv) was dissolved in degassed THF and 0.1 equiv CuSO₄·5H₂O solution and 0.4 molequiv Na ascorbate solutions were added, under nitrogen atmosphere. The azide was also dissolved in degassed THF and added to the mixture. The reaction was stirred under nitrogen, then, upon completion, QuadraSil™ MP metal scavenger was added to remove the copper, the mixture was filtered and concentrated in vacuo. When the purity of the

protected product was satisfactory, the crude was used directly in the following Zemplén-deprotection step.

General procedure for Zemplén deacetylation: 1 mol equiv acetylated compound was dissolved in distilled MeOH and 1 M freshly prepared NaOMe in MeOH was added to the solution (1.5 mol equiv NaOMe) to 0.1 M final concentration of the substrate. After completion, the reaction was neutralized with Amberlite® IR120 hydrogen form ion-exchange resin, filtered and concentrated in vacuo. The crude was purified by direct (CH₂Cl₂/MeOH) or reversed-phase flash chromatography (water/MeOH/MeCN, for ammonium salts 0.01% TFA was added), yielding the pure product. Compounds **5a–c**, **12a–c** and **16** were isolated as ammonium trifluoroacetate salts.

Compound 16: Obtained in 76% yield over two steps (CuAAC and deacetylation). *R*_f: 0.38 in water/MeOH = 1:1 + 0.01% TFA. ¹H NMR (400 MHz, CD₃OD): δ = 8.29 (s, 1H, H_{TRCH}), 7.30–7.18 (m, 8H, H_{12r}, H₁₃), 5.28 (s, 1H, H₁), 5.22 (dd, 1H, H_{2r}, *J*₁₋₂ = 1.0 Hz, *J*₂₋₃ = 5.1 Hz), 4.55 (d, 4H, H_{10r}, *J* = 2.6 Hz), 4.32–4.20 (m, 7H, H₃, H_{15r}, H_{16r}), 4.12–4.08 (m, 1H, C₂), 3.92–3.82 (m, 3H, H_{6a,b}, H_{7a}), 3.79–3.72 (m, 3H, H₅, H_{7b}, C₁), 3.69–3.60 (m, 3H, H_{8a,b}, H₄), 3.01–2.83 (m, 2H, C_{4r}, C₅), 2.03–1.89 ppm (m, 4H, C₃, C₆); ¹³C NMR (100 MHz, D₂O): δ = 177.9 (C₉); 177.6 (C₉); 142.5, 142.4 (C₁₄); 140.7 (C_{TRr}); 139.8 (C₁₁); 129.3 (C₁₃); 129.2 (C₁₂); 126.8 (C_{TRCH}); 98.3 (C₁); 77.1 (C_{C1} or C₅); 76.7 (C₅ or C_{C1}); 73.2 (C_{C2}); 71.6 (C₇); 71.1 (C₃); 69.0 (C₄); 65.8 (C₁₀); 65.5 (C₂); 63.0 (C₆); 45.2 (C₈); 44.6, 44.5 (C₁₅); 42.5 (C_{C4r}, C_{C5}); 36.3 (C₁₆); 30.8, 29.3 ppm (C_{C3r}, C_{C6}). MS (HRMS): *m/z* calculated for [C₃₅H₄₈ClN₆O₁₀]⁺: 747.3120 [*M*+H]⁺, found: 747.3123.

Sample preparation for ITC

ITC experiments were performed at 25 °C by using a TA Instrument Nano Isothermal Titration Calorimeter Low Volume (Nano ITC LV) with a 190 μL cell volume. Compound **16** and DC-SIGN ECD were prepared in 25 mM Tris-HCl at pH 8, 150 mM NaCl, 4 mM CaCl₂ and 4% DMSO. 100 μM of DC-SIGN ECD and 2.5 mM compound concentrations were used. The compound was stepwise injected (1.03 μL) into DC-SIGN solution by using 5 min intervals between injections. A blank titration (compound to buffer) was done for subtraction of dilution heat from the integrated data. A one-site binding model was fitted to the data (nanoAnalyse 2.20 TA), yielding dissociation constants (*K*_D) and binding enthalpies (Δ*H*).

Surface plasmon resonance (SPR) analysis

The extracellular domain (ECD) of DC-SIGN (residues 66–404) was overexpressed and purified as previously described. The SPR experiments were performed on a BIAcore T200 using a CM3 sensor chip. Flow cells were activated as previously described.^[18] Flow cell one was functionalized with BSA and blocked with ethanolamine and subsequently used as a control surface. Flow cells 2 and 3 were treated with BSA-Manα-1-3[Manα-1-6]Man (Dextra) (60 μg mL⁻¹) in 10 mM NaOAc pH 4 to reach different binding densities and blocked with ethanolamine. The final densities on flow cells 2 and 3 were 2579 and 2923 RU, respectively. The affinity of the various compounds for DC-SIGN ECD were evaluated via an established inhibition assay^[18] in which DC-SIGN ECD was injected at 20 μM alone or in the presence of increasing concentration of inhibitors (ranging from 0 to 5 mM). Injections were performed at 5 μL min⁻¹ using 25 mM Tris-HCl pH 8, 150 mM NaCl, 4 mM CaCl₂, 0.05% P20 surfactant as running buffer. The surface was regenerated by the injection of 50 mM EDTA.

Crystallization and X-ray data collection

HTX crystallization platform (EMBL) was used to screen conditions of co-crystallization with the hanging-drop vapor-diffusion method at 293 K. The drop was composed of a protein/reservoir ratio of 1:1 with protein concentrated at 5.54 mg mL⁻¹ in 150 mM NaCl, 4 mM CaCl₂, 25 mM Tris-HCl pH 8, 2% (v/v) DMSO buffer and 3.25 mM **16**. Among the crystallization hits obtained, the condition F04 (200 mM Mg(NO₃)₂, 20% PEG 3350) from the kit PEGs-Suite Qiagen was chosen for manual optimization screening with four different buffers (MES pH 6, HEPES pH 7, Tris pH 8 and Bicine pH 9), concentration of PEG 3350 (15%-25%) and Mg(NO₃)₂ concentration (from 150 to 200 mM). Finally, the best crystals were obtained in the following condition: 20% PEG 3350, 200 mM Mg(NO₃)₂, 100 mM MES pH 6.

Crystals were directly flash frozen in liquid nitrogen using Paratone-N as cryoprotectant. Data collection was performed at id30A-1 beamline (MASSIF-1), ESRF Grenoble, 3200 images were collected at 100°K, with an oscillation range of 0.05°, an exposure time of 0.039 s per image, and a wavelength of 0.966 Å. Data processing and refinement statistics are described in Table S2 (Supporting Information). Coordinates and associated structure factors have been deposited in the PDB database, code: 6GHV.

Analytical ultracentrifugation

Sedimentation velocity experiments were performed in a Beckman XL-1 analytical ultracentrifuge with a rotor Anti-50 (Beckman Coulter, Palo Alto, USA) and double-sector cells of optical path length 3 and 1.5 mm equipped of Sapphire windows (Nanolitics, Potsdam, DE). Samples were centrifuged at 42000 rpm (130000 g), at 20 °C. Sedimentation velocity profiles were acquired at 280 nm, every 10 min, with a 30 mm radial step size. DC-SIGN CRD or ECD concentration was fixed at 1.0 mg mL⁻¹ (56 and 26 μM, respectively), and compound **16** was used at variable concentration of 0, 15.6, 31.25, 62.5, 125, 250, and 500 μM. Solvent was 25 mM Tris-HCl pH8, 150 mM NaCl, 4 mM CaCl₂, 4 mM DMSO (density 1.0055 g mL⁻¹ and viscosity 1.0235 cp, estimated, neglecting DMSO, using the SEDNTERP software (available free at <http://sednterp.unh.edu/>). The partial specific volume (*v*) for DC-SIGN CRD and DC-SIGN ECD, was estimated from the amino acid compositions as 0.712, and 0.731 mL g⁻¹, respectively, and their molar mass (*M*) as 17.7 and 38.8 kDa, by using the SEDFIT software (available free at <https://sedfitsedphat.nibib.nih.gov/>). Data were analyzed in terms of continuous size distribution *c(s)* of sedimentation coefficients, *s*,^[19] by using SEDFIT. Peak integration and figures were done with the GUSSI software^[20] (<http://biophysics.swmed.edu/MBR/software.html>). The *s* and *M* values were combined in the Svedberg equation to calculate the hydrodynamic radius, *R*_H, or frictional ratio *f*/*f*_{min} (*f*/*f*_{min} = *R*_H/*R*_{min}, with *R*_{min} the radius of the anhydrous volume) [Eq. (1)]:

$$s = \frac{MW(1 - \rho v)}{N_A 6 \pi \eta R_H} \quad (1)$$

for DC-SIGN CRD considered as a monomer, *f*/*f*_{min} = 1.4 is derived from the experimental *s* = 1.8 S, which corresponds to a moderately anisotropic shape.^[21] The Svedberg equation was also used to derive corrected in water and at 20 °C *s*_{20w} values.

Acknowledgements

This project has received funding from the European Union Horizon 2020 research and innovation program under the

Marie Skłodowska-Curie grant agreement No. 642870 (Immunoshape. Fellowships to L.M. and S.A.). Support by the Italian Ministry of Research through a PRIN grant (prot. 2015SRNWJAM 002) and by the Spanish Ministry of Science MICINN (grants CTQ2014-57141-R and CTQ2017-88353-R, and fellowship BES 2015-071588 to J.G.C.) is acknowledged. The platforms of the Grenoble Instruct center (ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) and the Unitech Cospect platform in Milano (HRMS analysis) were used. SPR and MP3 platforms support from FRISBI (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). F.F. also acknowledge the French Agence Nationale de la Recherche (ANR) PIA for Glyco@Alps (ANR-15-IDEX-02). We are grateful to C. Rademacher for sharing structural file highlighting the secondary druggable binding sites of DC-SIGN described in Ref. [12].

Conflict of interest

The authors declare no conflict of interest.

Keywords: carbohydrates · DC-SIGN · glycomimetics · ligand design · virtual screening

- [1] a) G. D. Brown, J. A. Willment, L. Whitehead, *Nat. Rev. Immunol.* **2018**, *18*, 374–389; b) Y. van Kooyk, T. B. Geijtenbeek, *Nat. Rev. Immunol.* **2003**, *3*, 697–709.
- [2] a) S. Ordanini, N. Varga, V. Porkolab, M. Thepaut, L. Belvisi, A. Bertaglia, A. Palmioli, A. Berzi, D. Trabatonni, M. Clerici, F. Fieschi, A. Bernardi, *Chem. Commun.* **2015**, *51*, 3816–3819; b) A. Berzi, S. Ordanini, B. Joosten, D. Trabatonni, A. Cambi, A. Bernardi, M. Clerici, *Sci. Rep.* **2016**, *6*, 35373; c) S. Ordanini, G. Goti, A. Bernardi, *Can. J. Chem.* **2017**, *95*, 881–890.
- [3] a) N. Varga, I. Sutkeviciute, C. Guzzi, J. McGeagh, I. Petit-Haertlein, S. Gugliotta, J. Weiser, J. Angulo, F. Fieschi, A. Bernardi, *Chem. Eur. J.* **2013**, *19*, 4786–4797; b) V. Porkolab, E. Chabrol, N. Varga, S. Ordanini, I. Sutkeviciute, M. Thepaut, M. J. Garcia-Jimenez, E. Girard, P. M. Nieto, A. Bernardi, F. Fieschi, *ACS Chem. Biol.* **2018**, *13*, 600–608.
- [4] a) H. Feinberg, D. A. Mitchell, K. Drickamer, W. I. Weis, *Science* **2001**, *294*, 2163–2166; b) H. Feinberg, R. Castelli, K. Drickamer, P. H. Seeberger, W. I. Weis, *J. Biol. Chem.* **2006**, *282*, 4202–4209; c) J. Angulo, I. Díaz, J. J. Reina, G. Tabarani, F. Fieschi, J. Rojo, P. M. Nieto, *ChemBioChem* **2008**, *9*, 2225–2227.
- [5] a) S. Ng, N. J. Bennett, J. Schulze, N. Gao, C. Rademacher, R. Derda, *Bioorg. Med. Chem.* **2018**, *26*, 5368–5377; b) J. Aretz, U. R. Anumala, F. F. Fuchsberger, N. Molavi, N. Ziebart, H. Zhang, M. Nazaré, C. Rademacher, *J. Am. Chem. Soc.* **2018**, *140*, 14915–14925; c) L. R. Prost, J. C. Grim, M. Tonelli, L. L. Kiessling, *ACS Chem. Biol.* **2012**, *7*, 1603–1608.
- [6] a) E. D. Goddard-Borger, R. V. Stick, *Org. Lett.* **2007**, *9*, 3797–3800; b) N. Fischer, E. D. Goddard-Borger, R. Greiner, T. M. Klapotke, B. W. Skelton, J. Stierstorfer, *J. Org. Chem.* **2012**, *77*, 1760–1764; c) G. T. Potter, G. C. Jayson, G. J. Miller, J. M. Gardiner, *J. Org. Chem.* **2016**, *81*, 3443–3446.
- [7] a) K. Briner, A. Vasella, *Helv. Chim. Acta* **1987**, *70*, 1341–1356; b) R. R. Schmidt, J. Michel, M. Roos, *Liebigs Ann. Chem.* **1984**, *1984*, 1343–1357.
- [8] G. Zong, X. Liang, J. Zhang, L. Duan, W. Tan, D. Wang, *Carbohydr. Res.* **2014**, *388*, 87–93.
- [9] a) V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, *Angew. Chem. Int. Ed.* **2002**, *41*, 2596–2599; *Angew. Chem.* **2002**, *114*, 2708–2711; b) C. W. Tornøe, C. Christensen, M. Meldal, *J. Org. Chem.* **2002**, *67*, 3057–3064.
- [10] a) P. Aschwanden, C. R. J. Stephenson, E. M. Carreira, *Org. Lett.* **2006**, *8*, 2437–2440; b) F. Messina, M. Botta, F. Corelli, M. P. Schneider, F. Fazio, *J. Org. Chem.* **1999**, *64*, 3767–3769; c) S. Ma, B. Wu, X. Jiang, *J. Org. Chem.* **2005**, *70*, 2588–2593; d) R. J. Detz, M. M. E. Delville, H. Hiemstra, J. H.

- van Maarseveen, *Angew. Chem. Int. Ed.* **2008**, *47*, 3777–3780; *Angew. Chem.* **2008**, *120*, 3837–3840.
- [11] V. Porkolab, C. Pifferi, I. Sutkeviciute, S. Ordanini, M. Taouai, M. Thepaut, C. Vives, M. Benazza, A. Bernardi, O. Renaudet, F. Fieschi, *bioRxiv* **2019**, DOI <https://doi.org/10.1101/780452>.
- [12] J. Aretz, H. Baukmann, E. Shanina, J. Hanske, R. Wawrzinek, V. A. Zapol'skii, P. H. Seeberger, D. E. Kaufmann, C. Rademacher, *Angew. Chem. Int. Ed.* **2017**, *56*, 7292–7296; *Angew. Chem.* **2017**, *129*, 7398–7402.
- [13] J. Hanske, S. Aleksić, M. Ballaschk, M. Jurk, E. Shanina, M. Beerbaum, P. Schmieder, B. G. Keller, C. Rademacher, *J. Am. Chem. Soc.* **2016**, *138*, 12176–12186.
- [14] M. Thépaut, C. Guzzi, I. Sutkeviciute, S. Sattin, R. Ribeiro-Viana, N. Varga, E. Chabrol, J. Rojo, A. Bernardi, J. Angulo, P. M. Nieto, F. Fieschi, *J. Am. Chem. Soc.* **2013**, *135*, 2518–2529.
- [15] I. Sutkeviciute, M. Thepaut, S. Sattin, A. Berzi, J. McGeagh, S. Grudinin, J. Weiser, A. Le Roy, J. J. Reina, J. Rojo, M. Clerici, A. Bernardi, C. Ebel, F. Fieschi, *ACS Chem. Biol.* **2014**, *9*, 1377–1385.
- [16] a) G. Tabarani, J. J. Reina, C. Ebel, C. Vives, H. Lortat-Jacob, J. Rojo, F. Fieschi, *FEBS Lett.* **2006**, *580*, 2402–2408; b) G. Tabarani, M. Thépaut, D. Stroebel, C. Ebel, C. Vives, P. Vachette, D. Durand, F. Fieschi, *J. Biol. Chem.* **2009**, *284*, 21229–21240.
- [17] T. Tomašić, D. Hajšek, U. Švajger, J. Luzar, N. Obermajer, I. Petit-Haertlein, F. Fieschi, M. Anderluh, *Eur. J. Med. Chem.* **2014**, *75*, 308–326.
- [18] A. Tamburrini, S. Achilli, F. Vasile, S. Sattin, C. Vives, C. Colombo, F. Fieschi, A. Bernardi, *Bioorg. Med. Chem.* **2017**, *25*, 5142–5147.
- [19] P. Schuck, *Biophys. J.* **2000**, *78*, 1606–1619.
- [20] C. A. Brautigam, *Methods Enzymol.* **2015**, *562*, 109–133.
- [21] A. G. Salvay, G. Communie, C. Ebel, in *Intrinsically Disordered Protein Analysis: Vol. 2 Methods and Experimental Tools* (Eds.: V. N. Uversky, A. K. Dunker), Springer, New York, **2012**, pp. 91–105.

Manuscript received: July 23, 2019

Revised manuscript received: August 28, 2019

Accepted manuscript online: August 30, 2019

Version of record online: October 18, 2019